These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 6247892

  • 21. Thromboxane synthetase inhibition as antithrombotic strategy.
    Vermylen J, Defreyn G, Carreras LO, Machin SJ, Van Schaeren J, Verstraete M.
    Lancet; 1981 May 16; 1(8229):1073-5. PubMed ID: 6112447
    [Abstract] [Full Text] [Related]

  • 22. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
    Rajtar G, Cerletti C, Castagnoli MN, Bertelé V, de Gaetano G.
    Biochem Pharmacol; 1985 Feb 01; 34(3):307-10. PubMed ID: 3918536
    [Abstract] [Full Text] [Related]

  • 23. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
    Aiken JW, Shebuski RJ, Miller OV, Gorman RR.
    J Pharmacol Exp Ther; 1981 Nov 01; 219(2):299-308. PubMed ID: 6270303
    [No Abstract] [Full Text] [Related]

  • 24. [Synthesis of thromboxane A2: limiting stages of primary thrombocyte aggregation in humans initiated by arachidonic acid and its metabolic products].
    Mevkh AT, Basevich VV, Varfolomeev SD.
    Biokhimiia; 1984 Dec 01; 49(12):2035-40. PubMed ID: 6441604
    [Abstract] [Full Text] [Related]

  • 25. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour.
    Heptinstall S, Bevan J, Cockbill SR, Hanley SP, Parry MJ.
    Thromb Res; 1980 Oct 15; 20(2):219-30. PubMed ID: 7193919
    [No Abstract] [Full Text] [Related]

  • 26. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V, De Gaetano G.
    Eur J Pharmacol; 1982 Dec 03; 85(3-4):331-3. PubMed ID: 6295787
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Platelet desensitization induced by arachidonic acid is not due to cyclo-oxygenase inactivation and involves the endoperoxide receptor.
    Carmo LG, Hatmi M, Rotilio D, Vargaftig BB.
    Br J Pharmacol; 1985 Aug 03; 85(4):849-59. PubMed ID: 2994786
    [Abstract] [Full Text] [Related]

  • 31. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R, Nenci GG, Gresele P.
    J Pharmacol Exp Ther; 1995 Dec 03; 275(3):1497-505. PubMed ID: 8531121
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors.
    Kayama N, Sakaguchi K, Kaneko S, Kubota T, Fukuzawa T, Kawamura S, Yoshimoto T, Yamamoto S.
    Prostaglandins; 1981 Apr 03; 21(4):543-54. PubMed ID: 7196056
    [Abstract] [Full Text] [Related]

  • 33. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions.
    Needleman P, Bryan B, Wyche A, Bronson SD, Eakins K, Ferrendelli JA, Minkes M.
    Prostaglandins; 1977 Nov 03; 14(5):897-907. PubMed ID: 594391
    [Abstract] [Full Text] [Related]

  • 34. Lag-phase of arachidonic acid-induced secretion in responders and non-responders to the thromboxane-synthetase inhibitors: involvement of cyclic-AMP.
    Lecompte T, Joussemet M, Hainaut J.
    Thromb Res; 1984 Jul 01; 35(1):91-7. PubMed ID: 6089368
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Regulatory role of cyclic adenosine 3',5'-monophosphate on the platelet cyclooxygenase and platelet function.
    Fitzpatrick FA, Gorman RR.
    Biochim Biophys Acta; 1979 Jan 04; 582(1):44-58. PubMed ID: 216415
    [Abstract] [Full Text] [Related]

  • 37. Thromboxane A2 and the endoperoxides mediate canine platelet activation.
    Harris RH, Nichols R, Schmeling JW, Ramwell PW.
    Thromb Res; 1981 Sep 15; 23(6):521-32. PubMed ID: 6798707
    [No Abstract] [Full Text] [Related]

  • 38. Receptors and receptor mechanisms of endogenous platelet stimulatory and inhibitory mediators.
    MacIntyre DE, Bushfield M, MacMillan LJ, Moffat KJ, Murdoch FA, Thomson A, Rossi AG, McNicol A.
    Agents Actions Suppl; 1986 Sep 15; 20():45-62. PubMed ID: 3028106
    [No Abstract] [Full Text] [Related]

  • 39. Effect of minoxidil on platelet function and the synthesis of prostaglandins in platelets.
    O'Barr TP, Swanson EW, Fitzpatrick JE, Corby DG.
    J Lab Clin Med; 1989 Nov 15; 114(5):575-8. PubMed ID: 2553835
    [Abstract] [Full Text] [Related]

  • 40. Increased synthesis of prostaglandin-E-like material by platelets from patients with diabetes mellitus.
    Halushka PV, Lurie D, Colwell JA.
    N Engl J Med; 1977 Dec 15; 297(24):1306-10. PubMed ID: 917087
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.